Rheumatoid arthritis: recent advances on its etiology, role of cytokines and pharmacotherapy

J Alam, I Jantan, SNA Bukhari - Biomedicine & pharmacotherapy, 2017 - Elsevier
An autoimmune disease is defined as a clinical syndrome resulted from an instigation of
both T cell and B cell or individually, in the absence of any present infection or any sort of …

Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases

S Siebert, A Tsoukas, J Robertson, I McInnes - Pharmacological reviews, 2015 - ASPET
The human immune system involves highly complex and coordinated processes in which
small proteins named cytokines play a key role. Cytokines have been implicated in the …

Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised …

JS Smolen, AL Pangan, P Emery, W Rigby, Y Tanaka… - The Lancet, 2019 - thelancet.com
Summary Background Upadacitinib, an oral Janus kinase (JAK) 1-selective inhibitor,
showed efficacy in combination with stable background conventional synthetic disease …

Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a …

GR Burmester, Y Lin, R Patel… - Annals of the …, 2017 - ard.bmj.com
Objectives To compare efficacy and safety of sarilumab monotherapy with adalimumab
monotherapy in patients with active rheumatoid arthritis (RA) who should not continue …

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

C Gabay, P Emery, R Van Vollenhoven, A Dikranian… - The Lancet, 2013 - thelancet.com
Background Roughly a third of patients with rheumatoid arthritis treated with biological
treatments receive them as monotherapy. Tocilizumab—an inhibitor of interleukin 6 receptor …

Treatment with biologicals in rheumatoid arthritis: an overview

P Rein, RB Mueller - Rheumatology and therapy, 2017 - Springer
Management and therapy of rheumatoid arthritis (RA) has been revolutionized by the
development and approval of the first biological disease-modifying antirheumatic drugs …

Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year …

M Dougados, K Kissel, T Sheeran, PP Tak… - Annals of the …, 2013 - ard.bmj.com
Objective In patients with active rheumatoid arthritis (RA) despite methotrexate, to compare
the efficacy of adding tocilizumab to that of switching to tocilizumab monotherapy. Methods …

Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care …

A Souto, JR Maneiro, JJ Gomez-Reino - Rheumatology, 2016 - academic.oup.com
Objectives. To assess the proportion of RA patients who discontinued biologics in world
registries and health care databases and to identify causes and predictors of …

Real-world pattern of biologic use in patients with inflammatory bowel disease: treatment persistence, switching, and importance of concurrent immunosuppressive …

C Chen, AG Hartzema, H Xiao, YJ Wei… - Inflammatory bowel …, 2019 - academic.oup.com
Background and aims Medication persistence, defined as the time from drug initiation to
discontinuation of therapy, has been suggested as a proxy for real-world therapeutic benefit …

[HTML][HTML] Basic mechanisms of JAK inhibition

CMA Lin, FAH Cooles, JD Isaacs - Mediterranean Journal of …, 2020 - cyberleninka.ru
Over recent decades, treatment options for inflammatory diseases such as rheumatoid
arthritis (RA) have increased dramatically. These range from orally available steroids and …